Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Apperley

Showing results (131-140 of 140) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 140 results.
British Journal of Cancer|October 9, 1998
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levelsE J Kanfer, D McGuigan, D Samson, et al.
Leukemia|August 17, 2011
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibD Marin, I H Gabriel, S Ahmad, et al.
Leukemia|November 20, 2009
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA allelesB E Shaw, N P Mayor, N H Russell, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Bone Marrow Transplantation|July 1, 1997
European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationA Devergie, J F Apperley, M Labopin, et al.
Blood|November 10, 1998
Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working PartyE Carreras, H Bertz, W Arcese, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Bone Marrow Transplantation|February 20, 2013
Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipientsA W Loren, R Brazauskas, E J Chow, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Pageof 14

Showing results (131-140 of 140) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 140 results.
British Journal of Cancer|October 9, 1998
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levelsE J Kanfer, D McGuigan, D Samson, et al.
Leukemia|August 17, 2011
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinibD Marin, I H Gabriel, S Ahmad, et al.
Leukemia|November 20, 2009
Diverging effects of HLA-DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA allelesB E Shaw, N P Mayor, N H Russell, et al.
Bone Marrow Transplantation|August 30, 2008
Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplantB E Shaw, G J Mufti, S Mackinnon, et al.
Bone Marrow Transplantation|July 1, 1997
European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationA Devergie, J F Apperley, M Labopin, et al.
Blood|November 10, 1998
Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working PartyE Carreras, H Bertz, W Arcese, et al.
Leukemia|April 11, 2008
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibA Hochhaus, M Baccarani, M Deininger, et al.
Bone Marrow Transplantation|February 20, 2013
Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipientsA W Loren, R Brazauskas, E J Chow, et al.
The New England Journal of Medicine|November 5, 2013
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasJ E Cortes, D-W Kim, J Pinilla-Ibarz, et al.
Leukemia|March 5, 2020
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemiaA Hochhaus, M Baccarani, R T Silver, et al.
Pageof 14